"Human 11β-HSD1 IC _{50} Liver microsomal stability(% parent at 30 min) [n] Pharmacokinetics in dog Oral C _{max} (ng·mL ^{-1} ) Cl (mL·min ^{-1} ·kg ^{-1} ) t _{1/2} (h) Oral AUC _{(0➔} _{∞)} (ng.h·mL ^{-1} ) % F Plasma protein binding(% unbound) [n] Human hERG IC _{50} (μM) [n] Aqueous solubility at pH 7.4 (mg·mL ^{-1} ) [n] ","in HEK293 cells (nM) [n] ","24 ± 15 [31] Human 99 ± 1 [3] Dog 92 ± 5 [3] Rat 74 ± 1 [3] 4590 ± 546 4.68 ± 1.12 2.79 ± 0.84 31 730 ± 3746 170 ± 40 Human 30 ± 2 [2] Dog 44 ± 0 [1] Rat 26 ± 0 [2] >30 ± 0 [2] 0.200 ± 0 [1] ","7 ± 4 [5] Human 51 ± 3 [3] Dog 74 ± 1 [3] Rat 45 ± 5 [3] 3100 ± 908 8.68 ± 2.03 3.21 ± 1.61 9208 ± 2005 90 ± 40 Human 11 ± 2 [2] Dog 11 ± 0 [1] Rat 10 ± 1 [2] 3.1 ± 0.6 [2] 0.006 ± 0 [1] "
Pharmacokinetics in dog was conducted by i.v. and p.o. administration (n = 3 dogs per route). The number of individual experiments [n] for mea-
"surement of in vitro human 11β-HSD1 inhibition, liver microsomal stability, plasma protein binding, hERG inhibition and aqueous solubility are shown."
Date are reported as mean ± SD.
